2-Phenoxy-N-{2-[4-(2-phenoxyacetyl)piperazin-1-yl]ethyl}acetamide

Catalog No.: 
ACREPB095
CAS No.: 
547734-34-9
Molecular Formula: 
C22H27N3O4
Molecular Weight: 
397.48
2-Phenoxy-N-{2-[4-(2-phenoxyacetyl)piperazin-1-yl]ethyl}acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$214.00InquiryInquiry
5g90%$1059.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Phenoxy-N-{2-[4-(2-phenoxyacetyl)piperazin-1-yl]ethyl}acetamide
IUPAC Name2-phenoxy-N-(2-(4-(2-phenoxyacetyl)piperazin-1-yl)ethyl)acetamide
MDL No.MFCD02662231
Molecular FormulaC22H27N3O4
Molecular Weight397.48
SMILESO=C(NCCN1CCN(C(COC2=CC=CC=C2)=O)CC1)COC3=CC=CC=C3
InChI KeyNZLXALYBPRBGSH-UHFFFAOYSA-N
Synonym2-PHENOXY-N-(2-(4-(2-PHENOXYACETYL)PIPERAZINYL)ETHYL)ETHANAMIDE;2-phenoxy-N-{2-[4-(2-phenoxyacetyl)piperazin-1-yl]ethyl}acetamide;Acetamide, 2-phenoxy-N-[2-[4-(2-phenoxyacetyl)-1-piperazinyl]ethyl]-
CAS No.547734-34-9

Synthetic Route by SureRoute

1. ACREPB095 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACLVKE083 route compound structure diagram
    ACLVKE0833598-16-1In Stock
  4. Then
  5. ACREPB095 route product structure diagram
    ACREPB095547734-34-9
Inquiry

2. ACREPB095 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACREPB095 route product structure diagram
    ACREPB095547734-34-9
Inquiry

3. ACREPB095 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACREPB095 route product structure diagram
    ACREPB095547734-34-9
Inquiry

Comments (0)